Correction to: A phase I–II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia (Annals of Hematology, (2018), 10.1007/s00277-018-3229-5)

Martínez-Cuadrón, D.; Boluda, B.; Martínez, P.; Bergua, J.; Rodríguez-Veiga, R.; Esteve, J.; Vives, S.; Serrano, J.; Vidriales, B.; Salamero, O.; Cordón, L.; Sempere, A.; Jiménez-Ubieto, A.; Prieto-Delgado, J.; Díaz-Beyá, M.; Garrido, A.; Benavente, C.; Pérez-Simón, J. A.; Moscardó, F.; Sanz,; Montesinos, P.

Links

ORCID

Tools

Export citation

Search in Google Scholar

Correction to: A phase I–II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia (Annals of Hematology, (2018), 10.1007/s00277-018-3229-5)

Journal article published in 2018 by D. Martínez-Cuadrón, B. Boluda, P. Martínez, J. Bergua, R. Rodríguez-Veiga, J. Esteve, S. Vives, J. Serrano, B. Vidriales

, O. Salamero, L. Cordón, A. Sempere, A. Jiménez-Ubieto, J. Prieto-Delgado, M. Díaz-Beyá and other authors.

This paper was not found in any repository; the policy of its publisher is unknown or unclear.

Full text: Unavailable

Preprint: policy unknown

Upload

Postprint: policy unknown

Upload

Published version: policy unknown

Upload